Inducible CRISPR-Cas9 screening platform to interrogate non-proliferative cellular states

Gabriele Casagrande Raffi1, Hendrik J Kuiken2, Cor Lieftink2

  • 1Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Nature Protocols
|October 8, 2025
PubMed

Insights

This study introduces a new CRISPR screening protocol for non-proliferative cells. The inducible Cas9 system enables precise gene editing in states like senescence, aiding the discovery of new therapeutic targets.

Area of Science:

  • Molecular Biology
  • Genetics
  • Cancer Research

Background:

  • CRISPR screens are powerful tools for identifying genes essential for cell survival, proliferation, drug resistance, and synthetic lethal interactions.
  • Applying loss-of-function CRISPR screening to non-proliferative cells is challenging due to slow editing and low sensitivity in detecting guide RNA dropout.

Purpose of the Study:

  • To present a detailed protocol for performing CRISPR screens in non-proliferative states.
  • To enable precise temporal control over gene editing using an inducible Cas9 system.

Main Methods:

  • Development of an inducible Cas9 system for temporal control of gene editing.
  • Utilizing flow cytometry to measure editing efficiency.
  • Optimization of parameters for successful CRISPR screens in senescent cells.

Main Results:

  • Demonstration of a robust protocol for CRISPR screening in non-proliferative cells.
  • Successful application of the protocol to identify senolytic targets in senescent cells.
  • The protocol is accessible and can be completed within 8-12 weeks.

Conclusions:

  • The developed inducible CRISPR screening protocol overcomes limitations in studying non-proliferative cells.
  • This method facilitates the identification of therapeutic targets in diverse fields, including aging and cancer.
  • The protocol is adaptable for various non-proliferative states such as stem cell differentiation and immune cell development.